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Background. Diazabicyclooctanes (DBOs) are promising lactamase 27 
inhibitors. Some, including nacubactam (OP0595/RG6080), also bind PBP2, 28 
and have an enhancer effect, allowing activity against Enterobacteriaceae with 29 
MBLs, which DBOs do not inhibit. We tested the activity of nacubactam-30 
lactam combinations against MBL-producing Enterobacteriaceae. 31 
Materials/Methods. Test panels comprised: (i) 210 consecutive 32 
Enterobacteriaceae with NDM or VIM MBLs, as referred by UK diagnostic 33 
laboratories and, (ii) 99 supplementary MBL-producing Enterobacteriaceae, 34 
representing less prevalent phenotypes, species and enzymes.  MICs were 35 
determined by CLSI agar dilution.   Results.  MICs of nacubactam alone were 36 
bimodal, clustering at 1-8 mg/L or >32 mg/L: >85% of values for Escherichia 37 
coli and Enterobacter fell into the low-MIC cluster, whereas Proteeae were 38 
universally resistant and Klebsiella divided between the two 39 
groups.  Depending on the prospective breakpoint (4+4 or 8+4 mg/L), and on 40 
whether all isolates were considered or solely the Consecutive panel, 41 
meropenem/nacubactam and cefepime/nacubactam inhibited 80.3 to 93.3% of 42 
MBL producers, with substantial gains over nacubactam alone.  Against the 43 
most resistant isolates – comprising 57 organisms with MICs of nacubactam 44 
>32 mg/L, cefepime >128 mg/L and meropenem >128 mg/L – 45 
cefepime/nacubactam 8+4 mg/L inhibited 63.2% and meropenem/nacubactam 46 
8+4 mg/L inhibited 43.9%. Aztreonam/nacubactam - incorporating an MBL-47 
stable -lactam partner - was almost universally active against the MBL 48 
producers and, unlike aztreonam/ avibactam, had an enhancer effect. 49 
Conclusions.  Nacubactam combinations, including those using MBL-labile 50 
lactams, e.g. meropenem and cefepime, can overcome most MBL-mediated 51 
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resistance.  This behaviour reflects nacubactam’s direct antibacterial and 52 
enhancer activity. 53 
54 
Page 4 of 26 
Introduction 55 
Diazabicyclooctanes (DBOs) are potent non-lactam inhibitors of-56 
lactamases.1 Avibactam is the sole analogue so far licensed, partnered with 57 
ceftazidime. It is also in Phase III trials combined with aztreonam. Four further 58 
DBOs – ETX2514 (Entasis),2 nacubactam (RG6080/OP0595, Roche, Fedora, 59 
Meiji),3 relebactam (MK-7655, Merck),4 and zidebactam (WCK5107, 60 
Wockhardt)5 – have progressed into clinical development.    61 
DBOs inhibit most or all Class A and C -lactamases, whilst activity 62 
against Class D -lactamases varies with the particular enzyme and inhibitor.1-63 
5 Although DBOs do not inhibit MBLs (Class B -lactamases), which are an 64 
expanding problem worldwide6 this limitation may be overcome in either of two 65 
ways. Firstly, as with aztreonam/avibactam, the DBO can be combined with a 66 
monobactam, as these are stable to MBLs and need only to be protected from 67 
any co-produced ESBL or AmpC enzyme(s).7,8   Alternatively, several 68 
developmental DBOs – notably nacubactam, ETX2514 and zidebactam – have 69 
significant affinity for PBP2 of many Gram-negative species.3,5,9,10  This allows 70 
them to exert both a direct antibacterial effect and, like mecillinam (which also 71 
targets PBP2), an ‘enhancer’ mechanism, potentiating partner -lactams that 72 
bind to PBP3.  This combination of direct and enhancer-based activity means 73 
that combinations of MBL-labile -lactams with nacubactam, ETX2514 or 74 
zidebactam can retain activity against MBL-producing Enterobacteriaceae3,5,9 75 
(also Pseudomonas aeruginosa in the case of zidebactam10). Although the 76 
antibacterial activity of these DBOs is vulnerable to high-frequency mutational 77 
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resistance the enhancer effect is often retained against DBO-resistant 78 
mutants.3,5,9,11,12  79 
 We assessed the activity of nacubactam combinations against MBL 80 
producers by testing against isolates sent to the UK reference laboratory. 81 
 82 
Materials and methods 83 
Isolates 84 
Two groups of MBL-producing Enterobacteriaceae were used: the Consecutive 85 
and Supplementary Collections. The ‘Consecutive’ Collection comprised 158 86 
non-duplicate Enterobacteriaceae with NDM MBLs and 52 with VIM MBLs, as 87 
consecutively referred to PHE’s AMRHAI Reference Unit from UK diagnostic 88 
labs from May 2014 to Dec 2015.  The ‘Supplementary’ Collection comprised 89 
99 pre-2014 Enterobacteriaceae selected to add IMP enzymes, and to augment 90 
the numbers of under-represented species and aztreonam-susceptible 91 
phenotypes.  Bacterial species were identified by MALDI-ToF mass 92 
spectroscopy, whilst MBL genes were identified by PCR13,14 or Illumina-based 93 
WGS.12   94 
 95 
Antibiotics  96 
Nacubactam was from Roche (Basel, Switzerland); avibactam from TCG 97 
Lifesciences (Pune, India); aztreonam and cefepime from Alfa Aesar 98 
(Heysham, UK); and meropenem from Sequoia Research Products 99 
(Pangbourne, UK). 100 
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 101 
Susceptibility testing  102 
MICs were determined by CLSI agar dilution15 using Mueller-Hinton media from 103 
Oxoid/Thermofisher (Basingstoke, UK).  When end-points trailed, growth of >4 104 
colonies was counted as significant. Aztreonam, cefepime and meropenem 105 
were tested, as doubling dilutions, with nacubactam at 0, 1, 2 and 4 mg/L, or 106 
with avibactam at 4 mg/L.  ‘Synergy’ was defined as a >3 doubling dilution 107 
reduction in the partner -lactam MIC in the presence of the DBO. 108 
 109 
Results and Discussion 110 
 111 
Behaviour of nacubactam alone 112 
MIC distributions of nacubactam alone for the Combined Collection (i.e. 113 
Consecutive and Supplementary Collections combined, n =309) are shown in 114 
Table 1.  Values for Proteeae were almost all >32 mg/L, whereas those for 115 
other genera were bimodal, with peaks at 1-8 and >32 mg/L. MICs for most 116 
(>88%) E. coli and Enterobacter spp. fell into the lower peak, with few high 117 
values; those for Klebsiella spp. were widely scattered and complicated by 118 
trailing end points, but mostly fell into the higher peak, with 84/157 values >32 119 
mg/L. MICs of avibactam alone, which was included as a control, were <4 mg/L 120 
for just 3/309 isolates (1%), with values >4 mg/L for the remaining 99%. 121 
 122 
Analysis of the behaviour of nacubactam in combination 123 
Depicting the MIC distributions for combinations triple-action DBOs (i.e. those 124 
with direct antibacterial and enhancer effects as well as acting as -lactamase 125 
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inhibitors) is challenging. If MICs are expressed relative to the lactam, as is 126 
conventional for -lactam/-lactamase inhibitor combinations, values can be 127 
low either (i) because the DBO potentiates the lactam, or (ii) because the 128 
isolate is inhibited by the DBO itself.   In addition, a distinction must be drawn 129 
between the behaviour of combinations involving cefepime and meropenem, 130 
which are MBL-labile, and those involving aztreonam, which is stable to MBLs.  131 
For cefepime and meropenem combinations, a low MIC requires either 132 
antibacterial activity by the DBO or a strong enhancer effect whereas a low MIC 133 
for an aztreonam combinations may be achieved solely by inhibition of other 134 
coproduced lactamases.  MBL-producers lacking ESBL or AmpC activity are 135 
anyway susceptible to aztreonam. 136 
To capture these nuances, two presentations are provided.   Firstly, in 137 
Table 2, conventional MIC distributions are shown for the Combined and 138 
Consecutive Collections, and for various subsets.  These are compared with 139 
the MIC distributions for the unprotected lactam and for the corresponding 140 
combination with avibactam (4 mg/L), which lacks direct antibacterial and 141 
enhancer activities.   Secondly, Table 3 illustrates the proportions of different 142 
groups of isolates susceptible to meropenem, cefepime and aztreonam at 1, 2, 143 
4 or 8 mg/L, as determined in the presence of nacubactam at 0, 1, 2 or 4 mg/L, 144 
or with avibactam at 4 mg/L.  These lactam concentrations were chosen to 145 
straddle the current spectrum of EUCAST and CLSI breakpoints (EUCAST, 146 
cefepime and aztreonam S <1, R >4, meropenem, S <2, R >8; CLSI cefepime 147 
and aztreonam S <2, R >8, [with 4 and 8 mg/L designated ‘Dose-Dependent 148 
Susceptible for cefepime]; meropenem, S <1, R >4 mg/L).  149 
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 150 
 151 
MICs of meropenem and cefepime combined with DBOs 152 
 As would be expected, the great majority of MBL producers were resistant to 153 
unprotected meropenem and cefepime. Most, however, became susceptible to 154 
these agents when they were combined with nacubactam, 4 mg/L (Table 2).  155 
Thus, meropenem/nacubactam at 8+4 mg/L was active against 87.1% of the 156 
210 Consecutive isolates, which provide the best representation of currently 157 
circulating MBL producers, whilst cefepime/nacubactam 8+4 mg/L was active 158 
against 93.3% of these isolates. Corresponding proportions susceptible to 159 
meropenem/avibactam and cefepime/avibactam 8+4 mg/L were much smaller, 160 
at 24.8% and 22.4%, respectively.  161 
The wide activity of meropenem/nacubactam and cefepime/ 162 
nacubactam 8+4 mg/L combinations against Escherichia coli and Enterobacter 163 
spp., was substantially attributable to the direct antibacterial activity of 164 
nacubactam against these species (see Table 1). However 165 
meropenem/nacubactam 8+4 mg/L and cefepime/nacubactam 8+4 mg/L also 166 
were active against 127 (80.9%) and 141 (89.8%) of 157 MBL-positive 167 
Klebsiella spp. respectively (Table 2), whereas nacubactam 4 mg/L alone only 168 
inhibited only 40 (25.5%) of these isolates (Table 1). These gains in activity, 169 
relative to nacubactam alone, are best explained by the enhancer effect and 170 
are most clearly illustrated by data for the Combined Collection in Table 3.  171 
Overall, addition of nacubactam at 1, 2 or 4 mg/L allowed meropenem 8 172 
mg/L to inhibit 53.7%, 80.9% and 84.8% of all MBL producers; corresponding 173 
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proportions for equivalent cefepime combinations were 47.2%, 85.4% and 174 
90.0%, respectively whereas the proportions inhibited by nacubactam alone at 175 
1, 2 or 4 mg/L were only 12.6%, 35.0% and 49.2%, respectively (Table 1).  176 
Similarly-large gains in activity compared with nacubactam alone were 177 
apparent when other prospective meropenem and cefepime breakpoints were 178 
considered, when the Consecutive Collection alone was considered, or when 179 
only NDM Klebsiella spp. (as. the most populous group) were considered 180 
(Table 3).   181 
In general, cefepime/nacubactam combinations inhibited a slightly larger 182 
proportion of MBL producers than the corresponding meropenem/nacubactam 183 
combinations when the nacubactam concentration was 2 or 4 mg/L whereas 184 
the position reversed, with meropenem/nacubactam more active, when the 185 
nacubactam concentration was 1 mg/L.  The activity of 186 
meropenem/nacubactam and cefepime/nacubactam did not show any clear 187 
relationship to MBL type (IMP, NDM or VIM), nor to aztreonam susceptibility 188 
and resistance, which is a proxy for whether or not ESBL or AmpC enzymes 189 
are co-produced (Table 2). 190 
 Forty-seven isolates from the Combined Collection were resistant to 191 
meropenem/nacubactam 8+4 mg/L.  These comprised 30 Klebsiella spp., 9 192 
Proteeae, 4 Citrobacter spp., 3 E. coli and one Enterobacter spp.; 36 had NDM 193 
MBLs, 9 had VIM and two IMP.  Although Klebsiella spp. and NDM dominated, 194 
it should be recalled that these were the most populous species (159/309, 195 
51.5%) and MBL (200/309, 64.7%) type across the whole collection; the 196 
presence of 9/15 Proteeae and 4/10 Citrobacter spp. is more noteworthy and 197 
underscores the frequent resistance to these groups to the antibacterial action 198 
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of nacubactam (Table 1). Synergy between meropenem and 4 mg/L 199 
nacubactam was often weak or absent for Proteeae, with meropenem MICs 200 
reduced >8-fold in only 1/15 cases; synergy was greater with cefepime, where 201 
>8-fold MIC reductions were seen for 11/15 Proteeae.  202 
 203 
MICs of aztreonam combined with DBOs 204 
 As noted earlier, aztreonam combinations differ from the others considered 205 
here insofar as they utilise a lactam that is not a substrate for MBLs, meaning 206 
that low MICs are to be anticipated so long as the inhibitor inactivates any co-207 
produced monobactam-hydrolysing ESBL or AmpC enzyme.7,8  Thus, 208 
aztreonam/avibactam 4+4 mg/L inhibited 96.4% of the Combined Collection 209 
and 96.7% of the Consecutive Collection, rising to 98.1% and 99.5% 210 
respectively at 8+4 mg/L.  Aztreonam/nacubactam performed similarly, 211 
inhibiting 99.7% of the Combined Collection and 99.5% of the Consecutive 212 
Collection at either 4+4 or 8+4 mg/L.  Six isolates were not susceptible to 213 
aztreonam/avibactam at 8+4 mg/L; these comprised four E. coli and two 214 
Providencia spp. The sole isolate resistant to aztreonam/nacubactam at 4+4 or 215 
8+4 mg/L was an E. coli (MIC 32+4 mg/L) that was also highly resistant to all 216 
other nacubactam combinations, with MICs >128+4 mg/L for all cefepime and 217 
meropenem combinations.  218 
 219 
Nacubactam combinations against nacubactam-resistant isolates 220 
Isolates that are resistant to the antibacterial activity of both nacubactam and 221 
its MBL-labile antibiotic partners are of particular interest, because low 222 
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combination MICs here must depend upon the enhancer effect.9  Accordingly, 223 
Table 4 shows the MIC distributions of nacubactam combinations, compared 224 
with unprotected lactams and avibactam combinations, against the 110 225 
isolates for which the nacubactam MICs were >32 mg/L, and for the 57 of these 226 
that were highly resistant to meropenem and cefepime, with MICs >128 mg/L. 227 
 Nacubactam combinations retained activity against many of these 228 
difficult organisms. Thus, at 8+4 mg/L, meropenem/nacubactam inhibited 229 
61.8% of all isolates resistant to nacubactam at 32 mg/L, compared with only 230 
22.7% for meropenem/avibactam; similarly, cefepime/nacubactam 8+4 mg/L 231 
inhibited 75.5% of the Combined Collection compared with 15.5% for 232 
cefepime/avibactam.  Given that avibactam should inhibit co-produced ESBLs 233 
and AmpC enzymes as efficiently as nacubactam, the gain in activity of the 234 
nacubactam combinations relative to those involving avibactam is ascribed to 235 
the enhancer effect.  Against the 57 isolates that were highly resistant to 236 
cefepime and meropenem (MIC >128 mg/L) as well as to nacubactam (MIC 237 
>32 mg/L), 43.9% were inhibited by meropenem/nacubactam 8+4 mg/L and 238 
63.2% by cefepime/nacubactam 8+4 mg/L.  None of these 57 was susceptible 239 
to meropenem/avibactam or cefepime/avibactam 8+4 mg/L.  240 
Based on prospective 4+4 or 8+4 mg/L breakpoints, both 241 
aztreonam/avibactam and aztreonam/nacubactam had near universal activity 242 
against the nacubactam- and -lactam- resistant isolates.  In addition, and 243 
interestingly, nacubactam, unlike avibactam, potentiated aztreonam against 244 
many nacubactam-resistant (MIC >32 mg/L) isolates that were susceptible to 245 
aztreonam on CLSI criteria, with MICs <2 mg/L (n=29, Table 5).  Such isolates 246 
are unlikely to have significant AmpC or ESBL activity, firstly because of the 247 
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low aztreonam MICs and secondly because, if they did have such enzymes, 248 
aztreonam/avibactam synergy would be anticipated.  Accordingly, 249 
aztreonam/nacubactam, synergy here is interpreted as a further manifestation 250 
of the enhancer effect. 251 
  252 
Conclusion 253 
Along with boronates, DBOs are among the most promising new-generation 254 
lactamase inhibitors.1   A limitation is that DBOs do not directly inhibit MBLs, 255 
which are a rising global problem,6,16 whereas some of these enzymes are 256 
inhibited by developmental boronates such as VNRX-513317 (VenatoRx), 257 
though not by vaborbactam, which is the sole licensed analogue. Routes 258 
around this limitation are to combine the DBO with an MBL-stable monobactam, 259 
as with aztreonam/avibactam,7,8 or to use a triple-action DBO, such as 260 
nacubactam or zidebactam.3,5.9,10   Although the direct antibacterial activity of 261 
triple action DBOs is vulnerable to high frequency mutations that compensate 262 
for inhibition of PBP2,3,9,11,12 these commonly leave a functional enhancer 263 
effect; moreover, DBO-resistant mutants grow as round forms under DBO 264 
challenge,9,12 and the ability of these to sustain infection is questionable. 265 
 Despite utilising MBL-labile lactams, both meropenem/nacubactam 266 
and cefepime/nacubactam achieved wide activity against MBL producers, 267 
independently of the MBL type and the isolates’ aztreonam-resistance status. 268 
Activity did vary with species, with raised meropenem/nacubactam and 269 
cefepime/nacubactam MICs more frequent among Proteeae.  These are 270 
uncommon hosts for MBLs in most countries,16,18 though there is a scatter of 271 
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reports, notably of Providencia spp. with NDM enzymes in Latin America.19,20 272 
Meropenem/nacubactam or cefepime/nacubactam retained activity against 273 
many MBL producers that had high-level resistance to these molecules 274 
individually (Table 4).  This behaviour is believed to reflect the enhancer effect, 275 
contingent on simultaneous attack on PBP2 by nacubactam and PBP3 by the 276 
partner -lactam.  Although meropenem itself has significant affinity for PBP2, 277 
it is not so primarily directed against this target as imipenem, and also has 278 
potent affinity for PBP3.21.22 279 
 Aztreonam/nacubactam (and aztreonam/avibactam) achieved wider 280 
activity against MBL-producing Enterobacteriaceae than 281 
meropenem/nacubactam or cefepime/nacubactam. However, their overall 282 
spectrum is narrower, owing to aztreonam having limited activity against 283 
Pseudomonas and none against Gram-positive genera or anaerobes.23 284 
Moreover, aztreonam, which targets only PBP3, is more weakly bactericidal 285 
than cephalosporins and carbapenems, which target multiple PBPs.   On the 286 
other hand, some will consider a narrower spectrum to be ecologically 287 
preferable, and note that aztreonam has the advantages of limited cross-288 
allergenicity with other lactams and little selectivity for Clostridium 289 
difficile.24,25  290 
 The data presented here, coupled with the near universal activity of 291 
nacubactam combinations against isolates with non-metallo 292 
carbapenemases3,9 supports progression of nacubactam combinations into 293 
clinical development. 294 
 295 
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Table 1. MIC distributions of nacubactam, tested alone, by species, Combined Collection (n=309) 416 
 No isolates with indicated MIC (mg/L) 
Genus/Group <1 2 4 8 16 32 >32 Total 
Citrobacter spp.  1 1 2  3 3 10 
Enterobacter spp. 10 24 11   1 4 50 
Escherichia coli 22 29 14 3 3 1 5 77 
Klebsiella spp. 7 15 18 15 12 6 84 157 
Proteeaea    1   14 15 
Grand Total 39 69 44 21 15 11 110 309 
 417 
a Comprising 14 Providencia spp. and 1 Morganella morganii418 
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Table 2. MIC distributions of DBO 4 mg/L combinations, by species, MBL type and aztreonam resistance 419 
MIC 
(mg/L) 
No isolates with indicated MIC 
-Lactam/nacubactam 4 mg/L; isolate subsets Combined Collection (n=309) 
Consecutive 
Collection 
(n=210) 
Combined Collection, by species 
Combined Collection, 
by MBL type  
Combined Collection, 
by aztreonam MIC -Lactam-
nacubactam, 
4 mg/L 
-Lactam-
avibactam, 
4 mg/L 
-Lactam 
alone, no 
DBO Citro-
bacter 
Entero-
bacter 
E. 
coli 
Kleb-
siella 
Prot-
eeae IMP NDM VIM >2 mg/L <2 mg/L 
Meropenem  combinations         
<0.03 113 3 43 67 51   13 105 46 110 54 164 6 2 
0.06 16 1 2 2 15   1 13 6 12 8 20 0  
0.125 13 2   2 12     7 9 12 4 16 2  
0.25 6   2   6     2 6 4 4 8    
0.5 4       4     3 1 4   4    
1 3     2 5 1 2 5 1 5 3 8 3 1 
2 9       10 2   6 6 10 2 12 24 2 
4 12   1   13 2   12 4 12 4 16 13 18 
8 7   1 1 11 1 1 11 2 10 4 14 37 26 
16 7 2     7 4   10 3 8 5 13 27 32 
32 6 1     6 1   6 2 4 4 8 31 28 
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64 4 1     6   1 4 2 5 2 7 69 57 
128 6   1 2 8 3 1 11 2 13 1 14 47 75 
>128 4     1 3 1   5   3 2 5 50 68 
Cefepime combinations         
<0.03 125 4 45 69 61  14 114 51 119 60 179 8 1 
0.06 10  2 2 9   8 5 9 4 13 1 1 
0.125 13 1  1 15   6 11 14 3 17 2  
0.25 7   2 9  1 6 4 8 3 11 0  
0.5 6 1   5   3 3 5 1 6 1  
1 8    7 4  6 5 6 5 11 5  
2 10 2 1  9   11 1 12  12 22 3 
4 6 1   9  1 8 1 8 2 10 14 9 
8 11    17 2 1 13 5 13 6 19 15 15 
16 4  1  5 4  7 3 3 7 10 14 11 
32 4    5 1  6  5 1 6 12 21 
64 3 1   4  1 3 1 3 2 5 25 16 
128 1    1   1  1  1 51 34 
>128 2  1 3 1 4 1 8  6 3 9 139 198 
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Aztreonam combinations         
<0.03 188 9 48 74 128 8 17 174 76 176 91 267 17 1 
0.06 14  1  18 3 1 14 7 19 3 22 45 13 
0.125 5 1   9 1  5 6 10 1 11 87 20 
0.25 1  1  2  1 1 1 2 1 3 73 24 
0.5      1  1  1  1 44 6 
1 1   1    1   1 1 19 10 
2      2       7 16 
4    1    3  3  3 6 7 
8             5 7 
16             5 10 
32 1   1    1  1  1 1 17 
64              28 
128              35 
>128              115 
Total  210 10 50 77 157 15 19 200 90 212 97 309 309 309 
 420 
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Table 3.  Susceptibility  to DBO combinations compared with susceptibility to DBOs alone  421 
 
% of isolates susceptible to -lactam at stated concentration 
when combined with: 
 No DBO 
Nacubactam 
1 mg/L 
Nacubactam 
2 mg/L 
Nacubactam 
4 mg/L 
Avibactam 
4 mg/L 
Combined Collection (n=309)      
DBO alone - 12.6 35.0 49.2 1.0 
Meropenem, 1 mg/L + DBO 1.0 35.6 64.4 71.2 3.6 
Meropenem, 2 mg/L + DBO 1.6 40.1 70.2 75.1 11.3 
Meropenem, 4 mg/L + DBO 7.4 47.2 74.8 80.3 15.5 
Meropenem, 8 mg/L + DBO 19.1 53.7 80.9 84.8 27.5 
      
Cefepime, 1 mg/L + DBO 0.6 34.3 69.6 76.7 5.5 
Cefepime, 2 mg/L + DBO 1.6 39.5 74.8 80.6 12.6 
Cefepime, 4 mg/L+ DBO 4.5 41.7 79.6 83.8 17.2 
Cefepime, 8 mg/L + DBO 9.4 47.2 85.4 90.0 22.0 
      
Aztreonam, 1 mg/L + DBO 23.9 86.4 97.7 98.7 92.2 
Aztreonam, 2 mg/L + DBO 29.1 91.9 98.4 98.7 94.5 
Aztreonam, 4 mg/L+ DBO 31.4 95.8 99.0 99.7 96.4 
Aztreonam, 8mg/L + DBO 33.7 96.8 99.0 99.7 98.1 
      
Consecutive Collection (n=210)      
DBO alone - 14.8 35.7 50.0 1.4 
Meropenem, 1 mg/L + DBO 0.5 35.7 66.2 73.8 4.3 
Meropenem, 2 mg/L + DBO 1.0 40.5 73.8 78.1 11.9 
Meropenem, 4 mg/L + DBO 3.8 45.7 78.6 83.8 15.7 
Meropenem, 8 mg/L + DBO 11.4 52.9 84.3 87.1 24.8 
      
Cefepime, 1 mg/L + DBO 0.0 34.3 71.4 80.5 6.2 
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Cefepime, 2 mg/L + DBO 0.5 39.0 77.6 85.2 12.4 
Cefepime, 4 mg/L + DBO 2.4 41.9 83.8 88.1 17.1 
Cefepime, 8 mg/L + DBO 6.2 47.1 90.0 93.3 22.4 
       
Aztreonam, 1 mg/L + DBO 16.7 85.7 98.6 99.5 91.4 
Aztreonam, 2 mg/L + DBO 19.5 91.0 99.0 99.5 94.3 
Aztreonam, 4 mg/L + DBO 22.9 95.2 99.5 99.5 96.7 
Aztreonam, 8mg/L + DBO 25.2 96.2 99.5 99.5 99.5 
      
All NDM Klebsiella (n=104)      
DBO alone - 3.8 15.4 26.0 0.0 
Meropenem, 1 mg/L + DBO 0.0 10.6 44.2 57.7 0.0 
Meropenem, 2 mg/L + DBO 0.0 12.5 53.8 62.5 0.0 
Meropenem, 4 mg/L + DBO 0.0 16.3 62.5 71.2 1.0 
Meropenem, 8 mg/L + DBO 0.0 23.1 74.0 79.8 1.0 
      
Cefepime, 1 mg/L + DBO  0.0 10.6 52.9 62.5 1.0 
Cefepime, 2 mg/L + DBO 0.0 13.5 59.6 70.2 1.0 
Cefepime, 4 mg/L + DBO 0.0 16.3 73.1 76.9 1.0 
Cefepime, 8 mg/L + DBO 0.0 20.2 82.7 88.5 1.0 
      
Aztreonam, 1 mg/L + DBO 12.5 85.6 100.0 100.0 100.0 
Aztreonam, 2 mg/L + DBO 12.5 90.4 100.0 100.0 100.0 
Aztreonam, 4 mg/L + DBO 12.5 96.2 100.0 100.0 100.0 
Aztreonam, 8 mg/L + DBO 15.4 96.2 100.0 100.0 100.0 
 422 
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Table 4. Performance of DBO combinations against MBL producers highly resistant to nacubactam 423 
 
No. isolates with MIC of: 
 
Among all isolates with nacubactam MIC >32 mg/L (n=110) 
Among isolates with nacubactam 
MIC >32 mg/L and cefepime and 
meropenem MICs >128 mg/L (n=57) 
MIC 
mg/L MEM 
MEM/NAC 
4 mg/L 
MEM /AVI 
4 mg/L CPM 
CPM/NAC  
4 mg/L 
CPM/AVI  
4 mg/L AZT 
AZT/NAC  
4 mg/L 
AZT/AVI  
4 mg/L 
MEM/NAC 
 4 mg/L 
CPM/NAC  
4 mg/L 
AZT/ NAC  
4 mg/L 
             
<=0.03   2   5  1 74 7 2 2 34 
0.06   5   3  4 20 13 2 1 13 
0.125   7   12  6 10 41 2 3 5 
0.25   3   9  9 3 25   3 2 
0.5   2   5  2 1 19 1 2 1 
1   7   10 2 3  2 2 2  
2   12 5  10 9 4  1 4 4  
4 5 16 3 3 10 5 3 2  4 7 2 
8 10 14 17 1 19 1     8 12  
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16 10 11 5 3 10 6 3  2 3 4  
32 8 8 11 9 5 4 1   6 5  
64 20 7 24 9 5 11 12   7 5  
128 28 12 21 13 1 20 16   12 1  
>128 29 4 24 72 6 52 46   4 6  
Proportion (%) susceptible based upon prospective -lactam breakpoint of: 
1 mg/L 0.0 23.6 0.0 0.0 40.0 1.8 22.7 98.2 97.3 15.8 22.8 96.5 
2 mg/L 0.0 34.5 4.5 0.0 49.1 10.0 26.4 98.2 98.2 22.8 29.8 96.5 
4 mg/L 4.5 49.1 7.3 2.7 58.2 14.5 29.1 100.0 98.2 29.8 42.1 100.0 
8 mg/L 13.6 61.8 22.7 3.6 75.5 15.5 29.1 100.0 98.2 43.9 63.2 100.0 
 424 
Abbreviations: AVI, avibactam; AZT, aztreonam; CPM, cefepime, MEM, meropenem; NAC, nacubactam 425 
426 
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Table 5.  MIC distributions of aztreonam alone and in combination against aztreonam-susceptible (MIC <2 mg/L), nacubactam-resistant (MIC >32 mg/L) MBL 427 
producers 428 
 429 
 
No isolates with indicated aztreonam MIC (mg/L), in the presence of: 
MIC (mg/L) No DBO Nacubactam 1 mg/L Nacubactam 2 mg/L Nacubactam 4 mg/L Avibactam 4 mg/L 
<0.03 1 13 23 24 4 
0.06 4 11 4 3 9 
0.125 6 2 1 1 10 
0.25 9 3 1 1 4 
0.5 2    2 
1 3     
2 4     
  430 
